Price$11.24+0.06 (+0.58%)
01:30 PM06:15 PM
News · 26 weeks54+160%
2026-01-182026-07-12
Mix3090d
- SEC Filings14(47%)
- Other12(40%)
- Insider3(10%)
- Leadership1(3%)
Latest news
25 items- INSIDERDirector Patel Samir Rashmikant exercised 22,474 units of American Depositary Shares representing Ordinary Shares at a strike of $0.43 (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- SECSEC Form EFFECT filed by Akari Therapeutics plcEFFECT - Akari Therapeutics Plc (0001541157) (Filer)
- SECAmendment: SEC Form S-3/A filed by Akari Therapeutics plcS-3/A - Akari Therapeutics Plc (0001541157) (Filer)
- SECAmendment: SEC Form S-3/A filed by Akari Therapeutics plcS-3/A - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form EFFECT filed by Akari Therapeutics plcEFFECT - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory BoardGlobally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board. "Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment represents a significant addition to Aka
- SECAkari Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form S-3 filed by Akari Therapeutics plcS-3 - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory MilestonesTAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its previously announced PIPE through the consolidation of the remaining scheduled investment closings into a single funding event. Combined with warrant exercises completed in May, the Company received approximately $8.3 million in total capital during Q2 2026. "We appreciate the decision of our investor group to complete the remaining funding earlier than originally scheduled, and for some of these investors to further increase their commi
- SECSEC Form 8-K filed by Akari Therapeutics plc8-K - Akari Therapeutics Plc (0001541157) (Filer)
- SECAmendment: SEC Form S-1/A filed by Akari Therapeutics plcS-1/A - Akari Therapeutics Plc (0001541157) (Filer)
- INSIDERInterim CFO Farag Kameel D. was granted 18,830 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 1,161% to 20,452 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by CEO Gaslightwala Abizer4 - Akari Therapeutics Plc (0001541157) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Akari Therapeutics plcSCHEDULE 13G - Akari Therapeutics Plc (0001541157) (Subject)
- SECSEC Form DEF 14A filed by Akari Therapeutics plcDEF 14A - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing key themes emerging from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and Akari's positioning within the evolving ADC landscape. In the segment, Mr. Gaslightwala reflects
- SECSEC Form D filed by Akari Therapeutics plcD - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract AcceptanceCEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the "What This Means" video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor "What This Means" interview focused on the Company's recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. During the interview, Mr. Gaslightwala highlighted the significance of Akari's first ASCO abst
- SECSEC Form PRE 14A filed by Akari Therapeutics plcPRE 14A - Akari Therapeutics Plc (0001541157) (Filer)
- SECAkari Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Announces $5.5 Million Private Placement OfferingTAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial. "This financing reflects deep conviction from our long-term strategic investors and positions Akari to build on our
- SECSEC Form RW filed by Akari Therapeutics plcRW - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form 10-Q filed by Akari Therapeutics plc10-Q - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form NT 10-Q filed by Akari Therapeutics plcNT 10-Q - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics to Present at A.G.P.'s Annual Healthcare Company ShowcaseLive webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026. Management will discuss the Company's differentiated ADC pipeline, including progress across i
AKTX FAQ
6 questionsWhat does Akari Therapeutics plc do?
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in...Where does AKTX stock trade?
Akari Therapeutics plc (AKTX) is listed on NASDAQ.What sector and industry is AKTX in?
Akari Therapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AKTX?
Akari Therapeutics plc has had 3 recent analyst actions on file. The most recent action was from Maxim Group: Hold on 2026-04-08. Recent price targets range from $100.00 to $500.00.What companies are similar to AKTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AKTX side-by-side with any of them on Quantisnow.How can I track AKTX on Quantisnow?
Quantisnow aggregates Akari Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKTX to receive live email and push alerts on every new disclosure.